Amundi
CRBU icon

Amundi’s Caribou Biosciences CRBU Stock Holding History

Amundi’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,501
Closed -$24K – 2050
2023
Q1 		$24K Hold
4,501
– – ﹤0.01% 1950
2022
Q4 		$31.2K Hold
4,501
– – ﹤0.01% 1758
2022
Q3 		$48K Buy
+4,501
New +$41.9K ﹤0.01% 1677

Other funds holding CRBU

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Amundi's CRBU Position: Q2 2023 in Review

Amundi sold out of Caribou Biosciences (CRBU) in Q2 2023, closing a stake of 4,501 shares — an estimated $24K sold.

Amundi first reported a position in CRBU in Q3 2022 and held it in 3 quarters. The position peaked at $48K in Q3 2022. 121 funds tracked by Wall St. Rank hold CRBU as of Q2 2023.

  • Amundi reported no remaining Caribou Biosciences position as of Q2 2023 after selling out during the quarter.
  • Amundi sold 4,501 Caribou Biosciences shares in Q2 2023, an estimated $24K.
  • Amundi first reported a position in Caribou Biosciences in Q3 2022 and held it in 3 quarters.
  • Amundi's Caribou Biosciences position peaked at $48K in Q3 2022.
  • 121 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2023.

Based on Amundi's 13F filing for Q2 2023, filed 14 Aug 2023.